Cidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025

Rhea-AI Summary

Cidara Therapeutics (Nasdaq: CDTX) will report third quarter 2025 financial results and operational highlights after market close on Thursday, November 6, 2025, followed by a conference call and webcast at 5:00 PM ET (Conference ID: 10203589; US dial-in 1-844-825-9789).

The company develops drug‑Fc conjugate (DFC) immunotherapies using the Cloudbreak platform. Its lead DFC, CD388, is a long‑acting antiviral for universal influenza prevention; CD388 received FDA Fast Track designation in June 2023, reported positive top‑line Phase 2b NAVIGATE results in June 2025, and initiated the Phase 3 ANCHOR trial in September 2025.

Positive

• CD388 received FDA Fast Track designation in June 2023
• Positive Phase 2b NAVIGATE top‑line results announced June 2025
• Initiated Phase 3 ANCHOR trial in September 2025
• Scheduled Q3 2025 results and investor call on Nov 6, 2025

Negative

• None.

SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak^® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its third quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, November 6, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information

Date:	Thursday, November 6, 2025
Time:	5:00 PM Eastern Time
United States:	1-844-825-9789
International:	1-412-317-5180
Conference ID:	10203589
Webcast:	Link

About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak^® platform to develop novel DFCs comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment. Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the FDA. Cidara announced positive top-line results from its Phase 2b NAVIGATE trial in June 2025 and initiated its Phase 3 ANCHOR trial in September 2025. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com

MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com 

FAQ

When will Cidara (CDTX) report Q3 2025 results and hold the conference call?

Cidara will report Q3 2025 results after market close on November 6, 2025 and host a conference call at 5:00 PM ET.

How can investors join the Cidara (CDTX) Q3 2025 webcast and what is the conference ID?

Investors can join the webcast via the company site; dial in US 1-844-825-9789 or International 1-412-317-5180 using Conference ID 10203589.

What is Cidara's lead candidate CD388 and what recent clinical milestones has CD388 achieved?

CD388 is a long‑acting antiviral DFC for universal influenza prevention; it received FDA Fast Track in June 2023 and reported positive Phase 2b NAVIGATE top‑line results in June 2025.

Has Cidara (CDTX) started a Phase 3 trial for CD388 and when did it begin?

Yes; Cidara initiated the Phase 3 ANCHOR trial for CD388 in September 2025.

Where is Cidara Therapeutics headquartered and how can investors get more information?

Cidara is headquartered in San Diego, California; investors can visit www.cidara.com for more information.